An exploratory study investigating Pexastimogene-devacirepvec in combination with ipilimumab in patients with advanced melanoma

Trial Profile

An exploratory study investigating Pexastimogene-devacirepvec in combination with ipilimumab in patients with advanced melanoma

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2016

At a glance

  • Drugs Ipilimumab (Primary) ; Pexastimogene devacirepvec (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Sep 2016 According to a Transgene media release, the company expects the first data readout in 2017.
    • 05 Sep 2016 According to a Transgene media release, this trial is expected to initiate in the second half of 2016.
    • 19 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top